leisure time -WSS

leisure time

author：Wikipedia 2025-09-28 01:31:52 - browse：89773

The experimental Alzheimer’s drug lecanemab, hailed after it slowed patients’ cognitive decline in a clinical trial, may have contributed to the death in June of a patient in the study, STAT has learned.

One investigator on the study flagged the death, noting it came after the patient experienced bleeding in the brain, and concluded it was related to the drug, according to documents obtained by STAT. Eisai, the drugmaker behind lecanemab, disagreed, pointing to other possible factors, including a series of setbacks in preceding months — multiple falls, a heart attack, a respiratory infection, and mini-stroke-like events.

Though still under investigation, the death suggests that new medicines to treat Alzheimer’s, like medicines to treat anything else, will come with their own side effects and costs. It also raises the importance of waiting for the full lecanemab data before drawing conclusions based on the positive press release put out by Eisai and its partner Biogen last month.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Living organ donors deserve priority status for transplants

WSS

Biden administration plans revamp of organ transplant system

Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

Why liver experts renamed NASH to MASH, and NAFLD to MASLD

Science's Marcia McNutt, trailblazer for women, encounters sexism scandal

DeSantis can now import cheaper drugs. But will Biden get credit?

The SUPPORT Act is critical to fighting the opioid crisis

leisure time

leisure time

focus

In age of alternative facts, a scholarly course on calling out crap

Biotech reporter’s notebook: A sunnier mood at JPM 2024

Supreme Court strikes down use of affirmative action

New menopause drug shows promise in relief for hot flashes

Walensky prepares to leave CDC — and Congress — behind

Readout LOUD podcast: live from JPM 2024

As demand for Covid shots wanes, Moderna seeks its next success

Altering the blood type of lungs raises potential for universal organs for transplants

The cancer drug shortage isn’t new — and neither are the solutions

Xenotransplantation trials will require adjusting expectations, experts say

Wikipedia

Novo: Oral version of Ozempic leads to 15% weight loss

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

Bispecific antibodies are next new thing in cancer immunotherapy

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

Three issues to watch in global health in 2024

Idaho abortion case may prompt more restrictions in other states

entertainment

entertainment

leisure time

leisure time